Neurodevelopmental disorders represent significant areas of unmet need in healthcare. People affected by these disorders, predominantly children and young adults, can face a range of severe and devastating symptoms. In many cases, there are only limited or no treatments available. GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. GRIN Therapeutics is advancing promisi
In some cases, neurodevelopmental disorders are associated with a dysfunctional receptor known as NMDA. In the brain, NMDA receptors help regulate different physiological functions, including learning and memory. When these receptors are dysfunctional, neurodevelopmental syndromes can emerge with symptoms that include seizures, intellectual disabilities, and neurobehavioral symptoms. The ability to precisely control the activity of NMDA receptors could play a role in the treatment of a range of neurodevelop
Based on its mechanism of action as observed in preclinical studies, radiprodil could also play a role in the treatment of disorders associated with abnormal expression of NR2B including TSC and FCD. GRIN Therapeutics is planning to launch a proof-of-concept study to assess the potential benefits of radiprodil in the treatment of TSC and FCD. The trial will begin enrolling patients in early 2024.